Construction of Belarusian-Indian pharmaceutical plant on track to be completed by 2018 year-end

13.02.2018 09:48 / Belarus / India

MINSK - Construction of a joint Belarusian-Indian pharmaceutical plant JivaPharm in Kolyadichi is scheduled to be completed by the end of 2018, BelTA learned from the press service of the Belarusian government.

“Construction is on schedule. To date, the framework of the first floor of the building has been built. The Healthcare Ministry has already agreed the range of medications to be produced by the plant. These will be the preparations to treat people suffering from cancer, AIDS, hepatitis C and others,” the press service informed.

The Indian company Hetero and the Belarusian Healthcare Ministry signed the general agreement on strategic partnership in September 2017. The project provides for the production of antiretroviral drugs and medications of thea general group in tablets and capsules. Along with the shops to manufacture solid dosage forms the industrial building will incorporate an advanced lab to develop new products and to develop the small-batch production.

All in all, Belarus is building three pharmaceutical plants involving Indian investment in Kolyadichi, Skidel and Beshenkovichi.

The projects are supervised by Chairman of the Council of the Republic Mikhail Myasnikovich who is in charge of cooperation with India.

Source: BelTA
Back

Read also

25.05.2018 12:10
China is the world's largest food importer. Experts predict the further growth of the Chinese meat and dairy market. Belarus is ready to offer high-quality and eco-friendly products to Chinese consume...
25.05.2018 11:56
Meaningful and successful cooperation between Chinese and Belarusian contracting organizations serves as a great groundwork to implement joint infrastructure and manufacturing projects in third countr...
25.05.2018 11:44
Moscow Region is among biggest importers of Belarusian goods. In the first quarter of 2018 the trade between Belarus and Moscow Region continued its active growth and reached $1.3 billion, up 18% from...